Fiche centre
Henan Cancer Hospital
Zhengzhou — China
Essais liés17clinical trials
VilleZhengzhoulocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05152147
Essais cliniques associés
17| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ABSK021 | Myopathies | Phase 1 | NCT04192344 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor | RECRUITING |
| Ipatasertib | Cancer | Phase 3 | NCT05862285 | UmbrellaMAX — A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | RECRUITING |
| ZL-1310 | Cancer | Phase 1 | NCT06179069 | A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | RECRUITING |
| PF-08634404 | Cancer | Phase 2 | NCT07476287 | Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer | RECRUITING |
| ACE-232 tablets | Cancer | Phase 1 | NCT06801236 | Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer | RECRUITING |
| IBI3001 | Cancer | Phase 1 | NCT06349408 | IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | RECRUITING |
| Zanidatamab | Parkinson | Phase 3 | NCT05152147 | HERIZON-GEA-01 — A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | ACTIVE_NOT_RECRUITING |
| Prizloncabtagene Autoleucel | SEP | Phase 1/2 | NCT05800977 | ELEVATION — A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma | RECRUITING |
| ZL-1310 | Cancer | Phase 3 | NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | RECRUITING |
| Sonrotoclax | Cancer | Phase 3 | NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | RECRUITING |
| Tacabrutideg | Cancer | Phase 1/2 | NCT05006716 | CaDAnCe-101 — A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | RECRUITING |
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| Obinutuzumab | Cancer | Phase 3 | NCT06084936 | GLOBRYTE — A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | RECRUITING |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| PF-06821497 | Cancer | Phase 3 | NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | RECRUITING |
| Rina-S | Cancer | Phase 3 | NCT07604766 | RAINFOL-02 — An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China | RECRUITING |
| Sacituzumab govitecan-hziy | Cancer | Phase 3 | NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) | ACTIVE_NOT_RECRUITING |